An update from the PURPOSE 2 trial focused on adherence and pharmacokinetics data for lenacapavir, used to prevent HIV.
RBC Capital analyst Brian Abrahams raised the firm’s price target on Gilead (GILD) to $84 from $81 but keeps a Sector Perform rating on the ...
RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences (GILD – Research Report) today and set a price target of $84.00.
Zacks.com on MSN11h
Eyenovia Stock Tumbles on Termination of Phase III Myopia StudyEyenovia, Inc. EYEN announced the decision to terminate a phase III study evaluating its investigational drug-device product, ...
GlobalData on MSN11h
Gilead’s Livdelzi shows promise in PBC clinical trialThe analysis revealed that 81% of individuals treated with Livdelzi achieved a composite biochemical response.
AUSTIN, Texas, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA), a clinical-stage biotechnology company focused on developing a novel treatment for Alzheimer’s ...
The scope of Gilead Sciences' recent round of layoffs is coming into clearer view with the revelation that the company is ...
This report explores the benefits and challenges of NHS-industry partnerships aiming to catalyse improvements in the health ...
STEM South West is back for its sixth year, promising to be the biggest and best one yet - this time taking over Cork City ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback